A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, Recentin), in Patients With Advanced Solid Tumours.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Cediranib (Primary) ; Rifampicin
- Indications Prostate cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 30 Jan 2018 Planned End Date changed from 29 Dec 2017 to 31 Dec 2018.
- 18 Sep 2017 Planned End Date changed from 3 Dec 2016 to 29 Dec 2017.
- 22 Sep 2016 Planned End Date changed from 1 Jan 2017 to 1 Dec 2016.